NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst
News release
by
NanoViricides
London, UK
|
July 13, 2023 08:31 AM Eastern Daylight Time
Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides Inc (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. Savin gives an overview of what the company does, as well as its current operations and its financial situation. He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India.
Contact Details
Proactive Investors
+1 604-688-8158
